To elucidate the role of IgE-dependent mechanisms in inducing altered airway responsiveness in the atopic asthmatic state, the expression and actions of Fc receptor activation were examined in isolated rabbit tracheal smooth muscle (TSM) tissue and cultured cells passively sensitized with sera from atopic asthmatic patients or nonatopic͞ nonasthmatic (control) subjects. Relative to control tissues, the atopic asthmatic-sensitized TSM exhibited significantly increased maximal isometric contractility to acetylcholine (P < 0.01) and attenuated maximal relaxation responses and sensitivity (i.e., ؊log ED 50 ) to isoproterenol (P < 0.005). These changes in agonist responsiveness in atopic sensitized TSM were ablated by pretreating the tissues with a blocking mAb to the low affinity receptor for IgE, FcRII (i.e., CD23) or by depleting the sensitizing serum of its immune complexes. Moreover, in complimentary experiments, exogenous administration of IgE immune complexes to naive TSM produced changes in agonist responsiveness that were qualitatively similar to those obtained in the atopic asthmatic-sensitized state. Extended studies further demonstrated that, in contrast to their respective controls, atopic asthmatic serum-sensitized human and rabbit TSM tissue and cultured cells exhibited markedly induced mRNA and cell surface expression of FcRII, whereas constitutive expression of the IgG receptor subtype, Fc␥RIII, was unaltered. Finally, the up-regulated mRNA expression of FcRII observed following exposure of TSM to atopic asthmatic serum or to exogenously administered IgE immune complexes was significantly inhibited by pretreating the tissues or cells with anti-CD23 mAb. Collectively, these observations provide evidence demonstrating that the altered agonist responsiveness in atopic asthmatic sensitized airway smooth muscle is largely attributed to IgEmediated induction of the autologous expression and activation of FcRII receptors in the airway smooth muscle itself.
Bronchial asthma is characterized by airways inflammation, exaggerated airway reactivity to bronchoconstrictor agonists, and attenuated ␤-adrenoreceptor-mediated airway relaxation (1) (2) (3) . In individuals with atopic asthma, mast cell activation has been implicated in mediating the immediate bronchoconstrictor response acutely following antigen inhalation, a process involving IgE-mediated activation of the high affinity IgE receptor (FcRI), leading to cellular degranulation and the release of various mast cell-derived mediators (4) (5) (6) . The identification of Fc receptors on other cell types in the lung (e.g., mononuclear cells, eosinophils, and dendritic cells) suggests that, apart from mast cells per se, these other cell types may also serve to propagate the pro-inflammatory allergic pulmonary response, most likely via the orchestrated extended release of various cytokines (7) (8) (9) (10) (11) (12) (13) . Accordingly, immune complex͞Fc receptor interactions potentially underlie the progression of the airway inflammatory and bronchoconstrictor responses in asthma, wherein the immediate bronchoconstriction accompanying antigen exposure is followed by the development of the late phase asthmatic response involving various proinflammatory cells. Indeed, recent studies have demonstrated that expression of the inducible form of the low affinity IgE receptor (FcRII or CD23) is up-regulated on monocytes and alveolar macrophages (14) , as well as on circulating B lymphocytes (15, 16) isolated from atopic asthmatic subjects.
In light of the above evidence, together with our recent observations demonstrating that exposure of isolated rabbit and human airway smooth muscle (ASM) to atopic asthmatic serum induces the autocrine release and action of specific cytokines [notably interleukin (IL)-1␤] by the sensitized ASM cells (18) , the present study examined whether ASM cells have the capacity to intrinsically express Fc receptors and whether activation of these receptors is altered in the atopic asthmatic sensitized state and contributes to changes in agonist responsiveness of the ASM tissue. The results provide evidence that ASM cells intrinsically express Fc receptors and that the induced altered responsiveness of atopic asthmatic sensitized ASM is largely attributed to its autologously upregulated expression and activation of the FcRII receptor subtype. These findings identify a critical role for the ASM itself in autologously regulating IgE͞CD23-coupled changes in airway reactivity that characterize the asthmatic state.
MATERIALS AND METHODS
Preparation and Sensitization of ASM Tissue. New Zealand White rabbits were sacrificed with an overdose of pentobarbital (130 mg͞kg), the tracheae were removed, divided into ring segments, and incubated for 24 hr at room temperature in either (i) human serum containing IgE Ͼ1,000 units͞ml obtained from allergic patients with moderate to severe asthma and 4-5͞6ϩ radioallergosorbent test (RAST) positive (specific IgE concentration of more than 17.5 Phadebas RAST units͞ml) to Dermatophagoides pteronyssimus, Dermatophagoides farinae, and ragweed, and positive skin test to these antigens, or (ii) human serum from nonatopic nonasthmatic individuals with normal serum IgE levels (i.e., Ͻ70 units͞ml) (19) . In parallel experiments, tracheal smooth muscle (TSM) segments were incubated in either control serum or in atopic asthmatic serum that was (i) depleted of its Ig complexes by pretreatment with Sepharose Staph protein A (SpA), as described (20) ; (ii) coincubated with an anti-CD23 (40 g͞ml) blocking mAb; or (iii) coincubated with an anti-CD16 (2 g͞ml) blocking mAb. Finally, paired TSM segments were incubated for 24 hr in oxygenated DMEM, as described (21) The passive sensitization protocol described above was also conducted on human TSM isolated 1 hr postmortem from a 53-year-old male who had no evidence of lung disease, as well as a surgically resected human bronchial smooth muscle segment obtained from a 72-year-old female with peripheral lung carcinoma. The ASM isolates were incubated in either control or atopic asthmatic serum in the absence or presence of an anti-CD23 antibody, and subsequently examined for Fc receptor expression (see below).
Preparation and Sensitization of ASM Cells. ASM cells were isolated and subcultivated as described (22) . For the sensitization protocol, cells were grown to confluence in Ham's F-12 medium containing 20% fetal bovine serum. The culture medium was then replaced with Ham's F-12 medium for 24 hr and subsequently changed to F-12 containing (i) 10% human serum containing Ͼ1,000 units͞ml IgE obtained from allergic patients with moderate to severe asthma (as above), (ii) 10% human serum from nonatopic nonasthmatic (control) individuals (21), (iii) IgE immune complexes (15:5 g͞ml), or (iv) F-12 alone for the various time points.
Pharmacodynamic Studies. After incubation, the rabbit airway segments were suspended in organ baths for measurement of isometric contractility, as described (23) . Cholinergic contractility was assessed by cumulative administration of acetylcholine (ACh; 10 Ϫ10 to 10 Ϫ3 M). Thereafter, relaxation dose-response curves to isoproterenol (10 Ϫ10 -10 Ϫ4 M) were conducted in tissues halfmaximally contracted with ACh. The relaxant responses to isoproterenol were analyzed in terms of % maximal relaxation (R max ) from the active cholinergic contraction, and sensitivity to the relaxing agent was determined as the negative logarithm of the dose of the relaxing agent producing 50% of R max (pD 50 ) (i.e., geometric mean ED 50 value).
Determination of Fc Receptor mRNA by Reverse Transcription-PCR (RT-PCR). Total RNA was isolated from sensitized and control ASM cells and tissue as described (24) . cDNA was synthesized by using 2.5 g of total RNA isolated from the samples. The cDNA was primed with oligo(dT) [12] [13] [14] [15] [16] [17] [18] and with random hexamer nucleotides (N6) in the absence of signal from the former method. The Fc receptor primers used for PCR were based on the published sequences of the human Fc␥ -RI, -RII, -RIII, and FcRII genes (25, 26) and included the following primer sets: Fc␥RI: 5Ј primer, 5Ј-ATGTGGTTCTTGACAAC-TCTGCTC-3Ј and 3Ј primer, 5Ј-ATGTCTGTCTTCTTGAAG-GCTGGA-3Ј; Fc␥RIIA,C: 5Ј primer, 5Ј-GACTCCATTCAGT-GGTTCCA-3Ј; and 3Ј primer: 5Ј-GTCAGCTGTTTCATAGT-CATTG-3Ј; Fc␥RIIB: 5Ј primer, 5Ј-GACTCCATTCAGTGGT-TCCA-3Ј and 3Ј primer, 5Ј-CCCAACTTTGTCAGCCTCATC-3Ј; Fc␥RIII: 5Ј primer, 5Ј-AAGATCTCCCAAAGGCTGTG-3Ј and 3Ј primer, 5Ј-ATGGACTTCTAGCTGCACCG-3Ј; FcRII: 5Ј primer, 5Ј-CGTCTCTCAAGTTTCCAAG-3Ј and 3Ј primer: 5Ј-GCACTTCCGTTGGAATTTG-3Ј.
Rabbit-specific ␣-actin primers and human specific ribosomal protein L7 (RPL7) primers, based on the published sequence of the rabbit ␣-actin (27) and human RPL7 genes (28) , respectively, were used to control for the transcription level of each sample. The PCR number of cycles used were determined to be in the linear range of each PCR product. Equal aliquots of each PCR were then run on 1.2% agarose gels and transferred to a Zeta-probe membrane, and after capillary transfer, the DNA was immobilized by UV-crosslinking with a Stratalinker UV Crosslinker 2400. Prehybridization for 2-3 hr and hybridization for 20 hr, both at 42°C, were conducted as described (18) . The Fc␥RI, -RII, -RIII, FcRII, RPL7, and ␣-actin DNA levels were assayed by Southern blot analysis with 32 P-labeled probes, and fragments were subsequently sequenced for product confirmation. Of note, the 333-bp rabbit ASM CD23 RT-PCR products demonstrated Ϸ90% sequence homology with the human CD23 B-cell receptor gene. An immunofluorescence detection assay was also used to examine for FcRII surface receptor expression in rabbit ASM cells and tissue following 24-hr treatment with human control vs. atopic asthmatic serum, as described above. After fixation serial 3-to 5-m TSM sections were prepared and mounted on poly-L-lysine coated slides, and subsequently labeled overnight with primary mouse anti-human CD23 (FcRII) antibody. In control sections, the primary antibody was replaced by Igs of the same isotype following the manufacture's protocol (mouse IgG1 negative control). After subsequent repeat washing, FITC-labeled F(abЈ) 2 goat anti-mouse IgE (Fc) fragments were used as secondary antibody and incubated for 1 hr in 1:500-1,000 dilutions in PBS containing 0.5% BSA. The slides then were examined by using a fluorescent microscope.
Statistical Analysis. Unless otherwise indicated, results are expressed as mean Ϯ SE. Statistical analysis was performed by means of two-tailed paired Student's t test. P values Ͻ 0.05 were considered significant.
Reagents. The Fc␥RI, -RII, -RIII, FcRII, RPL7, and rabbit ␣-actin primers were obtained from Integrated DNA Technologies (Coralville, IA). ACh and isoproterenol hydrochloride were obtained from Sigma. The purified human IgE and IgG, and the goat-anti-human IgE and anti-human IgG antibodies were purchased from Biodesign International (Kennebunkport, ME). The purified rat IgE (rat myeloma) was purchased from Chemicon. The 3G8-FITC anti-Fc␥RIII and FITC-mouse mAb to the human CD23 receptors used in flow cytometric studies were purchased from Medarex and Caltag, respectively. The anti-CD23 blocking mAb (mAb135) was the gift of M. Sarfati (Montreal). The FcRII (CD23) antibody and F(abЈ) 2 -FITC fragments used in the immunofluoresence studies were purchased from Serotec. The immortalized B cell line 8.1.6 was provided by E. Mellins (University of Pennsylvania). The Fc␥RI, -RII, and -RIII cDNA probes and U937 cells were provided by S. McKenzie and D. Herrick (University of Pennsylvania). The human tissue was provided by the Cooperative Human Tissue Network (University of Pennsylvania), which is funded by the National Cancer Institute.
RESULTS

Role of Fc Receptors in Altered Responsiveness of Atopic Asthmatic Sensitized ASM.
We recently demonstrated that passive sensitization of isolated naive ASM tissue with human atopic asthmatic serum induces changes in the tissue's agonist-mediated constrictor and relaxant responsiveness that phenotypically resemble the pro-asthmatic state (19) . To examine whether these effects of atopic asthmatic serum are mediated, at least in part, by the presence of elevated levels of IgE in the sensitizing serum (see Materials and Methods), constrictor and relaxation responses were separately examined in TSM segments that were treated with human control or atopic asthmatic serum in the absence and presence of blockade of specific Fc receptors, or following depletion of immune complexes in the sensitizing serum by treatment with SpA (20) . As shown in Fig. 1 , relative to tissues incubated with 5258
Medical Sciences: Hakonarson and Grunstein Proc. Natl. Acad. Sci. USA 95 (1998) control serum (E), the maximal constrictor (T max ) responses to ACh were significantly enhanced in TSM passively sensitized with atopic asthmatic serum (F). Accordingly, the mean Ϯ SE T max values amounted to 121.7 Ϯ 5.3 and 146.0 Ϯ 15.5 g͞g TSM in the control and sensitized tissues, respectively (P Ͻ 0.01). The induced augmented constrictor responses to ACh, however, were largely prevented in atopic serum-sensitized tissues that were pretreated with an anti-CD23 blocking mAb (anti-CD23 mAb) ( Fig. 1 A, Ⅺ) or when the sensitizing serum was depleted of its immune complexes by pretreatment with SpA (Fig. 1B, Ⅺ) .
In separate studies, administration of the ␤-adrenergic receptor agonist isoproterenol elicited cumulative dose-dependent relaxation of the TSM precontracted with ACh (Ϸ40% T max ) (Fig. 2) . Relative to control TSM, the maximal relaxation responses (R max ) and sensitivities (pD 50 ; i.e., Ϫlog ED 50 ) to isoproterenol were significantly attenuated in the atopic asthmatic serum-sensitized TSM, wherein the mean R max values amounted to 26.0 Ϯ 5.1% vs. 47.0 Ϯ 4.7% in the control serum-treated TSM (P Ͻ 0.005), with corresponding pD 50 values averaging 5.82 Ϯ 0.16 and 6.59 Ϯ 0.11 Ϫlog M, respectively (P Ͻ 0.005). The attenuated isoproterenol-induced relaxation responses, however, were ablated in atopic serum-sensitized TSM that were pretreated with anti-CD23 mAb (Fig. 2 A) or when the sensitizing serum was initially depleted of its immune complexes with SpA (Fig. 2B) .
In contrast to the above observations, in control and serumtreated tissues, neither anti-CD23 mAb nor pretreatment of the control serum with SpA affected the tissues' subsequent contractility to ACh or relaxation responsiveness to isoproterenol (data not shown). Moreover, contrasting the above inhibitory effects of anti-CD23 mAb in atopic sensitized TSM, exposure of the sensitized tissues to a blocking mAb to the Fc␥RIII receptor, which is also expressed in ASM (see below), had no appreciable effect on the tissues' altered responsiveness to ACh or to isoproterenol (data not shown).
Effects of IgE and IgE Immune Complexes on ASM Responsiveness. In light of the above observations suggesting a role for IgE immune complex͞FcRII receptor interaction in mediating altered ASM responsiveness in the atopic asthmatic sensitized state, to further substantiate this mechanism we examined whether the sensitizing effects of the atopic asthmatic serum could be simulated by treatment of naive TSM with either exogenous IgE or IgE immune complexes. Constrictor and relaxant doseresponse relationships to ACh and isoproterenol, respectively, were separately compared in TSM exposed for 24 hr to vehicle alone (control) or varying concentrations of human IgE or IgE immune complexes (see Materials and Methods). Relative to their respective controls, the maximal constrictor responses to ACh were significantly (P Ͻ 0.05) enhanced in tissues treated with IgE immune complexes (i.e., 15:5 g͞ml of IgE͞anti-IgE), wherein the mean Ϯ T max responses amounted to 108.8 Ϯ 10.2 vs. 94.2 Ϯ 5.1 g͞g TSM wt in the control tissues (Fig. 3) . Comparably, the subsequent relaxation responses to isoproterenol in AChprecontracted TSM were markedly reduced in the IgE immune complex-treated vs. control tissues (Fig. 4) . Qualitatively, similar results were obtained in tissues treated with human IgE alone, although the changes in ACh-induced contraction and isoproterenol-induced relaxation were quantitatively less pronounced than those obtained in IgE immune complex-treated TSM (data not shown). Moreover, in contrast to the above effects of human IgE and IgE immune complexes, we found that treatment of rabbit ASM with rat IgE, which reportedly does not interact with CD23 Fc Receptor Expression in Atopic Asthmatic Sensitized ASM. Given the above pharmacodynamic results, we next examined whether cultured ASM cells and isolated ASM tissue express Fc receptors and whether the expression of these receptors is modulated in the atopic asthmatic sensitized state. The latter was examined by using RT-PCR and Fc receptor-specific primers for the different Fc␥ and Fc receptor subtypes, and the signals for the Fc␥, Fc and ␣-actin PCR products were quantitated on a PhosphorImager.
In contrast to the lack of detectable mRNA expression of Fc␥RI and Fc␥RII, ASM cells expressed mRNA for the Fc␥RIII receptor (Fig. 5A ). In parallel with the unaltered constitutive expression of ␣-actin, the Fc␥RIII signal did not temporally vary in cells treated for up to 24 hr with either control or atopic sensitized serum, and there were no significant differences in Fc␥RIII expression between control and sensitized cells. Expression of the high affinity IgE receptor, FcRI, was also undetectable in the ASM cells. On the other hand, as shown in Fig. 5B , mRNA expression of the low affinity IgE receptor, FcRII (i.e., CD23) was present in both the control and atopic asthmatic sensitized cells. Moreover, in contrast to control serum-treated ASM cells wherein the mRNA signal did not systematically vary with time, the intensity of the FcRII signal progressively increased at 6 and 24 hr in the atopic asthmatic serum-sensitized cells.
Similar results were obtained in comparable experiments conducted on isolated human TSM tissue wherein adjacent alternating sections were exposed for 24 hr to either control or atopic asthmatic serum. The Southern blots were then prepared using the above 32 P-labeled human-specific Fc␥RIII, FcRII, and RPL7 (157-bp) probes. As depicted in Fig. 6 , the signals for Fc␥RIII and RPL7 were similar in the control (CO) and atopic asthmaticsensitized (SE) tissue samples (Fig. 6A) . In contrast, FcRII expression, although detectable in the control samples, was markedly induced in the atopic asthmatic serum-treated tissues (Fig.  6B) , whereas the RPL7 signal was unaffected.
In light of the above observations, we next examined whether our observed up-regulation of FcRII expression in the atopic asthmatic sensitized state is attributed to activation of the FcRII receptor. As shown in Fig. 7 , by using ASM tissue sections isolated from the same human lung specimen we found that, whereas the tissue samples exposed to atopic asthmatic serum (SE) displayed markedly induced FcRII expression relative to control (CO) serum-treated samples, the up-regulation of FcRII expression was largely inhibited by pretreatment of the atopic serum-sensitized tissues with anti-CD23 mAb (SE ϩ ). Moreover, in separate complimentary experiments examining the effects of exogenous administration of IgE immune complexes on FcRII expression in cultured ASM cells, we found that treatment of the cells with IgE immune complexes induced progressive enhancement of FcRII mRNA expression (Fig. 8A ), resulting in a near 5-fold increase in FcRII expression at 24 hr (Fig. 8B) . In addition, in concert with the above ASM tissue studies, pretreatment of cells with anti-CD23 mAb significantly inhibited (i.e., by Ϸ40%) the magnitude of IgE immune complex-induced FcRII expression at 24 hr (Fig. 8B) .
Expression of Fc␥RIII and FcRII Cell Surface Proteins in Sensitized ASM. Given the above findings, we next examined whether ASM cells express Fc␥RIII and FcRII receptor proteins on their cell surface, examined by flow cytometry (see Materials and Methods). As shown in Fig. 9 , ASM cells expressed surface protein for both the low-affinity Fc␥RIII (Fig.  9A) and FcRII (Fig. 9B) receptors. In contrast to unaltered Fc␥RIII receptor expression after exposure of the cells for 24 hr to control or atopic asthmatic serum (Fig. 9A) , cell surface expression of the FcRII receptor was increased by Ͼ2-fold in the atopic asthmatic serum-treated vs. control serum-treated cells (Fig. 9B) . In additional comparative studies, we also examined for altered FcRII receptor expression in sensitized ASM cells and tissue by immunofluorescence staining (see Materials and Methods). In parallel with the above flow cytometric analysis, we found that surface immunofluorescence staining for the CD23 receptor protein was notably enhanced in the atopic asthmatic serum-treated cells and tissue (data not shown).
DISCUSSION
Allergic asthma is characterized by increased airway reactivity to bronchoconstrictor agonists, impaired ␤-adrenoreceptormediated airway relaxation, and inflammation of the airways (11, 12, 29) . The altered airway responsiveness in asthmatic individuals has been associated with elevations in total and antigen-specific serum IgE (30, 31) . Moreover, genetic analyses of 
FIG. 5. Comparison of expression of Fc␥RIII (A) and
FcRII (CD23) (B) receptor mRNAs by using RT-PCR in rabbit ASM cells after 0, 6-, and 24-hr treatment with 10% control serum and 10% atopic asthmatic sensitizing serum. Expression of ␣-actin was used to control for loading. cDNA from activated U937 cells (i.e., for Fc␥RIII) and the immortalized human B-cell line 8.1.6 (i.e., for FcRII) were used as positive controls. Note in contrast to Fc␥RIII, expression of FcRII is significantly up-regulated at 24 hr (i.e., Ͼ2-fold) after treatment with atopic asthmatic serum. FcRII (B) , and 157-bp RPL7 human cDNA probes. Paired human ASM samples were incubated with control (CO) or atopic asthmatic (SE) serum for 24 hr. cDNA was transcribed from total RNA primed with oligo(dT). PCR products were amplified by using human-specific Fc␥RIII, FcRII, and RPL7 primers, and then probed. Note the marked induction of FcRII expression in the atopic asthmatic serum-sensitized sample (i.e., Ͼ7.5-fold), whereas expression of Fc␥RIII or RPL7 was similar in both samples.
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Medical Sciences: Hakonarson and Grunstein Proc. Natl. Acad. Sci. USA 95 (1998) family members with allergic asthma have demonstrated a significant correlation between altered airway responsiveness and serum IgE levels (32, 33) . Although the mechanistic basis for this association remains to be identified, it has long been known that IgE can initiate immediate hypersensitivity reactions following allergen exposure by triggering the degranulation of mast cells via activation of the high affinity IgE receptor, FcRI (4-6). Progression of this initial IgE͞FcRI-coupled mast cell response into a subsequent late phase asthmatic response has been largely attributed to the orchestrated extended release of various cytokines by infiltrating pro-inflammatory cells (5, 7, 10, 11). However, more recent studies have demonstrated that expression of the inducible form of the low affinity IgE receptor (FcRII) is up-regulated on monocytes and lung alveolar macrophages (14, 17) as well as on circulating B lymphocytes (15, 16) isolated from atopic asthmatic individuals. Thus, these studies would suggest that, apart from mast cells per se, IgE͞Fc receptor interactions involving other pro-inflammatory cell types may also contribute to the presentation of allergic asthma. Although the above conventional thinking implicates both mast cells and other pro-inflammatory cells in the pathogenesis of asthma, the present study addressed the hypothesis that the resident ASM itself also plays an etiologic role in the pathobiology of the disease. The results provided compelling evidence demonstrating that ASM cells intrinsically express the low affinity receptor for IgE (FcRII) and that the induced altered responsiveness of ASM in the atopic asthmaticsensitized state is largely attributed to its autologously upregulated expression and activation of FcRII.
Our observed changes in responsiveness in the atopicsensitized tissues closely mimicked the pertubations in airway function that characterize the in vivo asthmatic condition, including exaggerated bronchoconstrictor responsiveness to contractile agonists and impaired airway relaxation to ␤-adrenoreceptor stimulation (18, 19) . In previously addressing the mechanistic link between exposure of naive airway tissue to atopic asthmatic serum and its resultant altered responsiveness, and by using the same experimental model described herein, we found that the latter effect is largely mediated by the induced autologous expression and autocrine action of the cytokine IL-1␤ in atopic-sensitized ASM (18) . Moreover, the mechanism of action of IL-1␤ in eliciting the altered responsiveness in sensitized tissues was attributed to its induced up-regulated expression of G i protein, specifically G i ␣ 2 and G i ␣ 3 , which inhibit intracellular cAMP accumulation (21) .
These findings, when coupled to the results of the present study, suggest that the sequence of events leading to cytokineinduced changes in ASM responsiveness in the sensitized state is initiated by IgE-coupled FcRII receptor activation involving the ASM itself. Indeed, in support of this concept, the present observations demonstrated that either depletion of serum immune complexes or pretreatment with a specific anti-CD23 blocking mAb largely prevented the changes in ASM responsiveness induced by exposure of the tissues to atopic asthmatic serum ( Figs. 1 and 2 ). Furthermore, in complimentary studies, exposure of naive ASM tissue to human IgE immune complexes produced changes in ASM responsiveness (Figs. 3 and 4) , which closely resembled those observed in the atopic-sensitized state. Thus, at least with respect to our experimental model, IgE-coupled Fc receptor activation principally involving the FcRII receptor in ASM itself appears to be fundamentally responsible for producing the pertubations in airway responsiveness that characterize the pro-asthmatic state.
In concert with the above pharmacodynamic results, our extended observations demonstrated the presence of constitutive FcRII and Fc␥RIII receptor mRNA and cell surface expression, both in cultured ASM cells and human ASM tissue (Figs. 5 and 6 ). Furthermore, in contrast to unaltered Fc␥RIII expression, FcRII was markedly enhanced in ASM exposed to the sensitizing atopic serum (Figs. 5 and 6 ). In considering these results, it is relevant to note that a number of studies have reported a direct correlation between serum IgE levels and FcRII and -RI expression (34) (35) (36) . Although these reports raised the notion of a possible common mechanism regulating the production of both IgE and its receptors, more recent evidence based on studies with different cell lines suggests that IgE itself may enhance FcRI (37, 38) or FcRII expression (39) (40) (41) . The latter concept is supported by our present observations, wherein we observed that the induced expression of FcRII in ASM treated with atopic asthmatic serum was largely inhibited in the presence of an anti-CD23 blocking antibody (Fig.  7) . Moreover, in extended support of the concept of IgEdependent modulation of FcRII expression, we also found that exogenously administered IgE immune complexes elicited an increase in FcRII expression (Fig. 8A) and, further, that this effect was significantly inhibited by pretreatment with anti-CD23 mAb (Fig. 8B) . Thus, our findings are consistent with the presence of a positive feedback system in ASM wherein IgE up-regulates the expression of its own low affinity receptor. This notion is in general agreement with previous studies which reported the presence of IgE-dependent Fc receptor induction in other cell types (37) (38) (39) (40) (41) .
In recent years, the complexity of transmembrane signaling via the FcRII receptor has been partially unraveled (42) (43) (44) (45) . Accordingly, in B-lymphocytes, a network involving antigen͞IgE immune complex molecules coupled to the FcRII receptor apparently serves to facilitate antigen presentation to antigenspecific CD4 ϩ (helper) T-lymphocytes, a process resulting in the expression of the CD4 ϩ ͞Th2 phenotype. The latter is associated with the release of such cytokines as IL-4 and IL-5 which are involved in B-lymphocyte switching to IgE production and eosinophil accumulation, respectively (44) , effects that have been recently documented in the lungs of immunized mice after inhaled antigen challenge (46) . In light of this, the results of the present study raise the consideration that, apart from inducing changes in airway responsiveness, up-regulated FcRII expression and activation in ASM cells may also play a role in modulating local airway immune responses. Indeed, this compelling concept is in part supported by our recent observation that ASM cells are autologously induced to release IL-1␤ in the atopic asthmatic-sensitized state (18) , a finding that, together with our present observations, suggests the presence of FcRII-coupled local stimulation of cytokine release and signaling.
In conclusion, the present study identified the presence and up-regulated expression of FcRII receptors in atopic asthmaticsensitized ASM, and further demonstrated that the latter phenomenon is associated with the induction of altered airway responsiveness in the atopic asthmatic-sensitized state. Given the important immunological and proinflammatory responses attributed to FcRII receptor activation, these findings identify a potentially important role and mechanism for the resident ASM in autologously inducing its own IgE-mediated state of altered responsiveness contributing to the atopic asthmatic condition. FIG. 9 . Flow cytometric analysis of Fc␥RIII and FcRII surface expression in rabbit ASM cells. Cells treated for 24 hr with either 10% control serum or 10% atopic asthmatic serum were stained with FITC-conjugated human mAbs specific for the low-affinity Fc␥RIII (A) and FcRII (CD23) (B) receptors. Activated B-cells (8.1.6) were used as a positive control for the CD23 receptor. The level of nonspecific background staining was measured in both the control-and atopic asthmatic-serum-treated cells by staining with FITC-conjugated isotype control antibodies. Note that the rabbit ASM cells express surface protein for both Fc␥RIII and FcRII receptors. In contrast to Fc␥RIII receptor expression, which is unaltered in the presence of atopic asthmatic serum, expression of the FcRII receptor is increased by Ͼ2-fold (i.e., from 17 to 36% in the presence of atopic asthmatic serum.
